Aravalli Rajagopal N
Department of Radiology, University of Minnesota Medical School, Minneapolis, MN, USA.
Stem Cells Cloning. 2010 May 3;3:81-92. doi: 10.2147/sccaa.s6886.
Primary hepatocellular carcinoma (HCC) is a common malignancy that has a poor prognosis because it is often diagnosed at an advanced stage. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are the current best options to treat liver cancer. However, problems associated with liver transplantation, such as shortage of donors, risk of immune rejection, and tissue damage following surgery provided the impetus for development of alternative therapies. The emerging field of stem cell therapy has raised hopes for finding curative options for liver cancer. Stem cells have the ability not only to proliferate after transplantation but also to differentiate into most mammalian cell types in vivo. In this review, progress on stem cell-derived technologies for the treatment of liver cancer is discussed.
原发性肝细胞癌(HCC)是一种常见的恶性肿瘤,由于其通常在晚期才被诊断出来,预后较差。HCC通常是由潜在的肝脏疾病发展而来,最常与肝硬化相关。手术切除和肝移植是目前治疗肝癌的最佳选择。然而,肝移植相关的问题,如供体短缺、免疫排斥风险和手术后的组织损伤,为替代疗法的发展提供了动力。新兴的干细胞治疗领域为找到肝癌的治愈方案带来了希望。干细胞不仅在移植后具有增殖能力,还能在体内分化为大多数哺乳动物细胞类型。在这篇综述中,将讨论干细胞衍生技术在治疗肝癌方面的进展。